ProfileGDS5678 / 1416926_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 93% 96% 95% 94% 94% 94% 95% 94% 93% 94% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8956893
GSM967853U87-EV human glioblastoma xenograft - Control 28.1208494
GSM967854U87-EV human glioblastoma xenograft - Control 38.0148993
GSM967855U87-EV human glioblastoma xenograft - Control 49.0917796
GSM967856U87-EV human glioblastoma xenograft - Control 58.4432195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8364194
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.8926494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1984294
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.3563395
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0339394
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7335993
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.2868594
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6333392
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8554293